Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,520.36
(
0.02%
)
US TECH 100
29,223.60
(
0.04%
)
Dow Jones
50,644.28
(
0.36%
)
Brent Oil
92.44
(
-4.69%
)
Bitcoin
74,885.15
(
-1.27%
)
News Focus
News Focus
Post# of 648882
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Tuff-Stuff

Send PM Follow Ignore
Followers 217
Posts 247348
Boards Moderated 2
Alias Born 04/06/2006

Tuff-Stuff

Re: Tuff-Stuff post# 506747

Friday, 04/26/2013 8:23:21 AM

Friday, April 26, 2013 8:23:21 AM

Post# of 648882
Avanir Pharmaceuticals (AVNR) jumps 14% premarket after the Committee for Medicinal Products for Human Use recommends approval of NUEDEXTA for the treatment of pseudobulbar affect. The company says the positive opinion is an important milestone on the road to getting "the only evidence-based treatment for PBA approved in the European Union."

Concentrate, and ASK the 8-Ball!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today